$ALVO News

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End

Alvotech announces completion of FDA surveillance inspection at Reykjavik facility

Alvotech 2026 Q1 - Results - Earnings Call Presentation

Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short

Alvotech Q1 Sales $105.900M Miss $140.847M Estimate

Alvotech Announces a Change in its Executive Team

Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress

Alvotech to Report Financial Results for the First Quarter of 2026

Here’s What the Street Thinks About Alvotech (ALVO)

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Alvotech shares are trading lower after Barclays and UBS lowered their respective price targets on the stock.

Alvotech shares are trading lower after Barclays and UBS lowered their respective price targets on the stock.

UBS Maintains Buy on Alvotech, Lowers Price Target to $6

Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4

Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative?

Alvotech Q4 Earnings Call Highlights